Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen Johns

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
CANNT Journal = Journal ACITN|August 24, 2012
The handwriting on the wall: program transformations utilizing effective change management strategiesAnita Amos, Colleen Johns, Nordia Hines, et al.
Clinical Therapeutics|February 13, 2017
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza<sup>®</sup>Miguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed Daak, et al.
Journal of Clinical Lipidology|May 16, 2017
Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>)-based formulationMiguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed A Daak, et al.
Clinical Therapeutics|February 13, 2017
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current GuidanceKevin C Maki, Colleen Johns, William S Harris, et al.
Frontiers in Pharmacology|August 1, 2022
Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary FibrosisJutaro Fukumoto, Muling Lin, Mudassir Meraj Banday, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
CANNT Journal = Journal ACITN|August 24, 2012
The handwriting on the wall: program transformations utilizing effective change management strategiesAnita Amos, Colleen Johns, Nordia Hines, et al.
Clinical Therapeutics|February 13, 2017
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza<sup>®</sup>Miguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed Daak, et al.
Journal of Clinical Lipidology|May 16, 2017
Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>)-based formulationMiguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed A Daak, et al.
Clinical Therapeutics|February 13, 2017
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current GuidanceKevin C Maki, Colleen Johns, William S Harris, et al.
Frontiers in Pharmacology|August 1, 2022
Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary FibrosisJutaro Fukumoto, Muling Lin, Mudassir Meraj Banday, et al.
Pageof 1